Abstract
The standard of care for the prevention of variceal rebleeding, i.e. combination of variceal ligation and beta-blockers, is uniformly applied to all cirrhotic patients with a previous variceal bleed. Risk stratification would allow tailor therapy. Preliminary results of individual patient data meta-analysis of randomized controlled trials comparing the efficacy of variceal ligation and beta-blockers with either therapy alone to prevent rebleeding indicate that the efficacy of these therapies is different between Child A and Child B/C patients. In Child A, combination therapy is associated with lower rebleeding rate, but without differences in survival. In Child B/C, and compared to variceal ligation alone, combination therapy is associated with lower rebleeding and mortality. Although combination therapy should continue to be the standard of care for variceal rebleeding prevention, it should take into account that beta-blockers are the mainstay of such therapy. Covered TIPS is recommended as the second line therapy for patients who have failed standard combination therapy, and also for those likely to fail combination therapy or with complications of portal hypertension other than bleeding
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Garcia-Tsao G, Sanyal AJ, Grace ND et al; Practice Guidelines Committee of the American Association for the Study of Liver Diseases; Practice Parameters Committee of the American College of Gastroenterology (2007) Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 46:922–938
de Franchis R, Baveno V Faculty (2010) Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 53:762–768
Gonzalez R, Zamora J, Gomez-Camarero J et al (2008) Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med 149:109–122
Cheung J, Zeman M, van Zanten SV, Tandon P (2009) Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices. Aliment Pharmacol Ther 30:577–588
Thiele M, Krag A, Rohde U, Gluud LL (2012) Meta-analysis: banding ligation and medical interventions for the prevention of rebleeding from oesophageal varices. Aliment Pharmacol Ther 35:1155–1165
Albillos A, Tejedor M (2014) Secondary prophylaxis for esophageal variceal bleeding. Clin Liver Dis 18:359–370
Puente A, Hernández-Gea V, Graupera I et al (2014) Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int 34:823–833
Ahmad I, Khan AA, Alam A et al (2009) Propranolol, isosorbide mononitrate and endoscopic band ligation - alone or in varying combinations for the prevention of esophageal variceal rebleeding. J Coll Physicians Surg Pak 19:283–286
García-Pagán JC, Villanueva C, Albillos A et al; Spanish Variceal Bleeding Study Group (2009) Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut 58:1144–1150
Lo GH, Chen WC, Chan HH et al (2009) A randomized, controlled trial of banding ligation plus drug therapy versus drug therapy alone in the prevention of esophageal variceal rebleeding. J Gastroenterol Hepatol 24:982–987
Lo GH, Lai KH, Cheng JS et al (2000) Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology 32:461–465
de la Peña J, Brullet E, Sanchez-Hernández E et al (2005) Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial. Hepatology 41:572–578
Kumar A, Jha SK, Sharma P et al (2009) Addition of propranolol and isosorbide mononitrate to endoscopic variceal ligation does not reduce variceal rebleeding incidence. Gastroenterology 137:892–901
Abdel-Rahim AY, Abdel-Ghany MS, El-Kholy B (2000) Band ligation alone versus band ligation and propranolol in the management of bleeding oesophageal varices. Am J Gastroenterol 95:2442
Sollano JD, Chan MM, Babaran RP et al (2001) Propranolol prevents rebleeding after variceal ligation. Gastrointest Endosc 53:AB143
Lo GH, Lai KH, Cheng JS et al (2001) The effects of endoscopic variceal ligation and propranolol on portal hypertensive gastropathy: a prospective, controlled trial. Gastrointest Endosc 53:579–584
Villanueva C, Aracil C, Colomo A et al (2009) Clinical trial: a randomized controlled study on prevention of variceal rebleeding comparing nadolol + ligation vs. hepatic venous pressure gradient-guided pharmacological therapy. Aliment Pharmacol Ther 29:397–408.
Lo GH, Chen WC, Lin CK, et al (2008) Improved survival in patients receiving medical therapy as compared with banding ligation for the prevention of esophageal variceal rebleeding. Hepatology 48:580–587.
Papatheodoridis GV, Goulis J, Leandro G et al (1999) Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: a meta-analysis. Hepatology 30:612–622
Khan S, Tudur Smith C, Williamson P et al (2006) Portosystemic shunts versus endoscopic therapy for variceal rebleeding in patients with cirrhosis. Cochrane Database Syst Rev (4):CD000553
Escorsell A, Bañares R, García-Pagán JC et al (2002) TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial. Hepatology 35:385–392
Bureau C, Garcia-Pagan JC, Otal P et al (2004) Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology 126:469–475
de Souza AR, La Mura V, Reverter E et al (2012) Patients whose first episode of bleeding occurs while taking a β-blocker have high long-term risks of rebleeding and death. Clin Gastroenterol Hepatol 10:670–676
Salerno F, Cammà C, Enea M et al (2007) Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 133:825–834
Sersté T, Melot C, Francoz C et al (2010) Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52:1017–1022
Luca A, Miraglia R, Caruso S et al (2011) Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 60:846–852
Han G, Qi X, Guo W, Niu J, Bai M, Fan D (2012) Transjugular intrahepatic portosystemic shunt for portal vein thrombosis in cirrhosis. Gut 61:326–327
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this paper
Cite this paper
Albillos, A. et al. (2016). Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care. In: de Franchis, R. (eds) Portal Hypertension VI. Springer, Cham. https://doi.org/10.1007/978-3-319-23018-4_31
Download citation
DOI: https://doi.org/10.1007/978-3-319-23018-4_31
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-23017-7
Online ISBN: 978-3-319-23018-4
eBook Packages: MedicineMedicine (R0)